Scholar Rock Holding SRRK
NASDAQ SRRK
$55.10 -0.83 (-1.49%)
As of: Sep 4, 2026 · 1:37 PM EDT

Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026)

Scholar Rock Holding (SRRK) posted quarterly Cash from Financing Activities of $193.8 million for Q1 2026, up 4548.26% year-over-year from $4.2 million in Q1 2025, and up 164.42% quarter-over-quarter from $73.3 million in Q4 2025.

Analysis

Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $193.8 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 4548.26% year-over-year to $193.8 million; the TTM figure through Mar 2026 stood at $418.0 million (up 19.2% YoY), while the FY2025 annual figure was $228.4 million, down 35.3% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $193.8 million, up from $73.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $346.4 million in Q4 2024, with the low at -$970000.0 in Q4 2022.
  • The 5-year median for Cash from Financing Activities is $4.7 million (2023), against an average of $63.1 million.
  • The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 123.66% in 2022, then jumped 86929.52% in 2025.
  • Scholar Rock Holding's Cash from Financing Activities stood at -$970000.0 in 2022, then surged by 10051.44% to $96.5 million in 2023, then soared by 258.82% to $346.4 million in 2024, then slumped by 78.84% to $73.3 million in 2025, then jumped by 164.42% to $193.8 million in 2026.
  • Business Quant data shows SRRK's Cash from Financing Activities at $193.8 million in Q1 2026, $73.3 million in Q4 2025, and $144.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - 2.42 Bn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - -273.15 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 27.18 Mn
10 Scholar Rock Holding 7.19 Bn 7.19 Bn - 83.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 83.12 Mn
Mar 31, 2026 193.79 Mn
Dec 31, 2025 73.29 Mn
Sep 30, 2025 144.47 Mn
Jun 30, 2025 6.47 Mn
Mar 31, 2025 4.17 Mn
Dec 31, 2024 346.37 Mn
Sep 30, 2024 166,000.00
Jun 30, 2024 -33,000.00
Mar 31, 2024 6.53 Mn
Dec 31, 2023 96.53 Mn
Sep 30, 2023 280,000.00
Jun 30, 2023 4.69 Mn
Mar 31, 2023 1.08 Mn
Dec 31, 2022 -970,000.00
Sep 30, 2022 -451,000.00
Jun 30, 2022 195.77 Mn
Mar 31, 2022 481,000.00
Dec 31, 2021 39.70 Mn
Sep 30, 2021 1.91 Mn